Scientists inhibit cancer gene
Potential therapy for up to 30 percent of human tumors
Attempts to inhibit activated Ras have had limited success until now, but the Huntsman Cancer Institute researchers explain that they have discovered an enzyme that, when inhibited, appears to reduce the incidence of Ras-induced tumors in mice.
Matthew K. Topham, MD, assistant professor of internal medicine at the University of Utah School of Medicine and lead investigator on the study, explains that the research team had originally been testing a group of enzymes that regulate the function of the Ras gene. These enzymes, called diacylglycerol kinases (DGKs), are implicated in tumor growth.
"When we began our investigation using a type of DGK, called DGK iota, we thought that its absence would cause more tumors to develop, as has happened with other DGKs we have tested. This time, though, when we tested mice with an activated Ras gene, but an absent DGK iota gene, the number of tumors was significantly reduced," Topham says. "This result is interesting because it happened when the Ras gene was activated. The implication is that a drug therapy could be developed to reduce tumors caused by Ras without significant side effects."
The researchers used mice that were bred to have a highly "expressed" - meaning highly active - mutant of the Ras oncogene. Such mice were first developed years ago. Prior studies had demonstrated that these mice were very prone to tumors. For the new study, the Huntsman Cancer Institute team deleted the DGK iota gene in these mice and found that they developed few tumors, while mice with an intact DGK iota gene and an activated Ras exhibited significantly more tumors.
Topham says his team will now examine more closely the mechanism behind how DGK iota works to inhibit tumor formation.
Original Publication: Proceedings of the National Academy of Sciences, 2005.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.